The goal of MRI perfusion is to provide noninvasive estimates of functional hemodynamic parameters. The purpose of this article is to review commonly used perfusion techniques: arterial spin-labeled, dynamic susceptibility-weighted and dynamic contrast-enhanced imaging. The advantages, disadvantages and limitations of each technique are discussed. Specific applications in tumor imaging are discussed in terms of determining tumor diagnosis, prognosis and treatment failure versus response.

**Perfusion methods**

The common goal of all MRI perfusion techniques is to generate an image contrast that models the concentration of blood in tissues. DSC and DCE techniques derive information about blood flow from the effects of gadolinium contrast on the MR signal. Repeated successive acquisitions at short intervals permit the estimation of various hemodynamic perfusion parameters. Common DSC and DCE perfusion parameters are summarized in Table 1. In DSC perfusion, the better established and more widely used of the two techniques, T2- or T2*-weighted images are obtained to track the first pass transit of contrast, which is assumed to be intravascular. In DCE perfusion, T1-weighted images are obtained to measure changes in tissue concentration. ASL does not use gadolinium contrast.

- **DSC T2*-weighted MRI perfusion**
  
  DSC perfusion can be obtained using both spin echo (SE) and gradient echo (GRE) sequences. SE images employ a 180° refocusing pulse that eliminates T2* effects and, similar to a diffusion-weighted sequence, only measures the signal loss that results from the diffusion of protons through gadolinium-induced magnetic field gradients, as well as from direct intravascular T2-changes. The effect is strongest where gadolinium contrast varies most sharply over a short distance (relative to the typical diffusion distance at the time-scale of the experiment; i.e., the echo
Table 1. Common dynamic susceptibility contrast and dynamic contrast-enhanced perfusion parameters.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Dynamic susceptibility contrast</th>
<th>Dynamic contrast-enhanced</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weighting</td>
<td>T2*</td>
<td>T1</td>
</tr>
<tr>
<td>Sequence</td>
<td>Gradient echo and echo planar</td>
<td>SPGR</td>
</tr>
<tr>
<td>TE (ms)</td>
<td>20–50</td>
<td>1.5</td>
</tr>
<tr>
<td>TR (ms)</td>
<td>1250–1500</td>
<td>8</td>
</tr>
<tr>
<td>Flip angle (°)</td>
<td>35–45</td>
<td>25</td>
</tr>
<tr>
<td>Slice thickness (mm)</td>
<td>3–5</td>
<td>3–5</td>
</tr>
<tr>
<td>Matrix (pixels)</td>
<td>64 × 64 or 128 × 128</td>
<td>128 × 128 or 256 × 256</td>
</tr>
<tr>
<td>FOV (cm²)</td>
<td>24</td>
<td>24</td>
</tr>
<tr>
<td>Contrast preload (ml/kg)</td>
<td>0 or 0.02–0.2</td>
<td>–</td>
</tr>
<tr>
<td>Contrast dose (ml/kg)</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Contrast injection rate (ml/s)</td>
<td>2–5</td>
<td>2–5</td>
</tr>
<tr>
<td>Saline flush (ml)</td>
<td>20</td>
<td>40</td>
</tr>
<tr>
<td>Time per volume of 10–15 slices (s)</td>
<td>1</td>
<td>5–10</td>
</tr>
<tr>
<td>Total imaging volumes</td>
<td>60–120</td>
<td>40–50</td>
</tr>
<tr>
<td>Total time (min)</td>
<td>1.5–2</td>
<td>3–6</td>
</tr>
</tbody>
</table>

FOV: Field of view; SPGR: Spoiled gradient recalled acquisition in the steady state; TE: Time to echo; TR: Repetition time.

From the time–contrast curve. Measurement of the arterial input function permits the quantification of cerebral blood flow (CBF) and mean transit time. Owing to the many assumptions that must be made in the calculation of these parameters, values are usually reported relative to an area of brain parenchyma presumed to be normal, usually in the contralateral hemisphere. Relative values have been shown to be less sensitive to choice of arterial input function [16] and, in some cases, are more accurate in predicting pathology [17]. Two commonly applied DSC parameters are relative CBV (rCBV), used to estimate perfusion normalized to contralateral white matter, and percentage signal recovery (PSR), used to estimate leakiness by measuring the recovery of the signal–intensity curve to baseline.

The DSC perfusion model presumes an intact blood–brain barrier (BBB). The most common model is the single compartment model, based on the intravascular indicator dilution theory where all of the administered contrast agent remains confined within the vasculature [18]. This assumption is invalid in most pathologic conditions – wherever there is contrast enhancement, the BBB must be compromised. The extravasation of contrast agent alters the T1 relaxation time and modifies the MRI signal intensity, complicating any estimation of perfusion parameters. Techniques have been developed to compensate for this leakage of contrast agent from the vasculature into the interstitial space and/or recirculation effects [19,20], for example, by preloading with a dose of intravenous contrast before scanning begins. The amount of contrast administered for the preload dose may vary according to the local institutional preferences by an order of magnitude from 0.01 to 0.10 mmol/kg, with no consensus on the optimal preload dose to yield the most accurate perfusion metrics [21,22]. T1 effects may also be reduced by using low flip angle gradient echo sequences and dual-echo sequences [23,24]. Using a low flip angle (35°) gradient echo sequence and a single contrast dose, Essock-Burns et al. found that blood volume metrics from both a nonlinear fitting analysis and nonparametric analysis of the time–concentration curve were able to predict areas of microvascular hyperplasia in 72 tissue samples from 35 glioblastoma patients [5]. Post hoc corrections may also be performed using γ variate curve fitting or an arterial input function [25], although these may incompletely correct the underlying artifacts. In the former of these, the change in...
R_{2^*} (\Delta R_{2^*}) curve is modeled from the sum of the \gamma variate function and the leakage caused by the contrast bolus using a nonlinear fitting procedure (Figures 1 & 2) [5]. Without correction of T1-weighted leakage and T2/T2*-weighted effects, the accuracy of DSC perfusion has been described as only 81% [21]. Other authors have described DSC perfusion as inconsistent in the absence of any correction [22,26], potentially limiting its clinical applicability [19].

**DCE T1-weighted MRI perfusion**

DCE perfusion also requires the intravenous administration of gadolinium contrast to exploit the leakiness of pathologic capillaries to provide useful information about microvascular structure. As with DSC perfusion, a gadolinium bolus is dynamically tracked through tissue to estimate hemodynamic parameters. Unlike DSC perfusion, DCE perfusion uses T1-weighted images to measure changes in the tissue concentration of intravenous contrast over time. Image contrast depends on the observed T1 shortening of the gadolinium bolus and increase in MRI signal as it passes through the tissue of interest. The relationship between contrast concentration and signal intensity depends on precontrast tissue relaxivity, flip angle, repetition time and proton density, which is somewhat more complex than in the case of DSC perfusion [27,28]. Since the calculation of contrast concentration from signal intensity does not presume an intact BBB, additional information is available about the movement of the tracer across the capillary membrane and into the tissue. Multiple methods for deriving so-called model-based parameters have been reported. Most commonly, a two-compartment model of the local tissue environment is assumed [29]. The tracer flows into the capillary system from the arterial circulation and, if the BBB is disrupted, can extravasate into the interstitium. The two compartments of the model are the intravascular plasma space, which represents contrast material in blood plasma, and the extravascular extracellular space (EES), which represents the portion of tissue into which the tracer can diffuse. DCE signal is calculated from the plasma volume (Vp) estimating the plasma volume fraction, the Ve estimating the extravascular–extracellular fraction in the EES and the cellular volume estimating the cellular fraction (Figure 3). A primary goal of DCE perfusion is to estimate the volume transfer coefficient (K_{trans}), which measures the passage of the tracer from the intravascular plasma space to the EES. Although it depends on multiple factors including capillary permeability, capillary surface area and plasma flow, K_{trans} can be considered to be a measure of capillary leakiness [30]. A popular model assumes that Ve >> Vp, and therefore simply solves for K_{trans} and Ve while ignoring Vp. The details of the derivation of these parameters to describe vascular leakiness, which includes measurement of the

---

**Figure 1. Dynamic susceptibility contrast perfusion with \gamma variate curve fitting.** (A) Axial contrast T1-weighted image shows an ill-defined heterogeneously enhancing glioblastoma centered in the left occipital lobe. (B) Axial relative cerebral blood flow (rCBV) map overlaid on a contrast T1-weighted image shows a control region of interest (ROI) in the normal contralateral white matter, ROI\textsubscript{1}, in the heterogeneously enhancing periphery and ROI\textsubscript{2}, in the nonenhancing cystic/necrotic center. (C) The color scale defines areas of increasing perfusion as changing from blue to green to yellow to red. T2\textsuperscript{*} signal intensity time curve reveals increased rCBV (1.9) in ROI\textsubscript{2} and decreased rCBV (0.4) in ROI\textsubscript{1}. The smooth red curve is the \gamma variate fitting curve for ROI\textsubscript{2}, whose uncorrected curve shown in green continues to increase after the contrast injection due to leakage and T1 effects related to disruption of the blood–brain barrier (that may potentially lead to underestimation of the rCBV).

For color images please see online at www.futuremedicine.com/doi/pdf/10.2217/iim.13.50.
arterial input function from a large vessel, are beyond the scope of this article, but many excellent reviews on this topic are available [28,29,31,32]. The first and currently only US FDA-approved DCE perfusion module is nordicICE (Nordic-NeuroLab, WI, USA).

Arterial spin labeling

ASL does not require any exogenous gadolinium contrast. Instead, arterial blood water molecules are used as the freely diffusible intrinsic contrast. First, protons within a slice proximal to (upstream from) the imaging volume are tagged with an inversion pulse. Dynamic scans through the volume of interest are then evaluated before and after the arrival of the tagged spins in order to obtain perfusion information [33–35]. In general, techniques are divided into continuous ASL (CASL), pulsed ASL (PASL) and pseudocontinuous ASL (p-CASL).

In CASL, a continuous labeling radiofrequency pulse or a long train of pulses (over several seconds) is applied to adiabatically invert arterial blood spins through the labeling slice. This is based on the theory of adiabatic fast passage. CASL provides more effective spin labeling and a higher signal than PASL. These advantages are countered by the fact that macromolecules in the volume of interest, which have a broad range of resonance frequencies, become saturated over time by the continuous radiofrequency pulses and transfer this magnetization back to the tissue in the form of a high specific absorption rate [36].

PASL applies short inversion pulses (over a few milliseconds) to a thick slab of inflowing spins close to the imaging volume. Multiple PASL sequences have been developed to address specific shortcomings of the basic technique [37,38]. PASL techniques are easier to implement and have a lower specific absorption rate than CASL. PASL also demonstrates high labeling efficiency over a wide range of blood flow velocities.

p-CASL applies a train of rapidly repeating low-tip pulses and alternating sign magnetic field gradients to perform continuous labeling. This provides a higher signal-to-noise ratio and does not require any additional complicated modeling or saturation pulses as compared with PASL. p-CASL and PASL have been described as having superior intersite reproducibility to CASL [39], although p-CASL has been advocated as the default technique for clinical ASL perfusion due to its insensitivity to vessel geometry and other advantages over PASL [40]. Further improvements to the p-CASL technique, such as modified p-CASL, may overcome the cumulative tipping that occurs in PASL to maintain the ASL signal [41].

ASL principally provides an estimate of the absolute CBF, most commonly using a single compartment model under the assumption that water diffuses freely across vascular membranes [42]. Some investigators have employed models of two or more compartments with concordant results [43]. CBF measurements correlate well with perfusion values obtained by other means [44]. Hirai et al. examined 24 patients with glioma and...
found similar reproducibility and intermodality agreement for tumor blood flow (TBF) using DSC and ASL perfusion techniques [45].

**Summary of perfusion techniques**

Each of the three main MR perfusion techniques has unique advantages and disadvantages. DSC perfusion is the best established and most widely studied of the three techniques. It is relatively easy to implement and data analysis is straightforward [46]. DSC offers highest contrast-to-noise ratios and, since the majority of schemes use echo planar imaging, acquisitions are rapid and easy to incorporate into routine practice. Greater experience with this technique and a broader base of published data will provide guidance in the interpretation of results.

DCE perfusion offers lower contrast-to-noise ratios but greater spatial resolution. The ability to quantify microvascular leakiness is an important advantage, for example, in grading gliomas [47], where Ktrans has been suggested to be the single best indicator of a high-grade tumor. On the other hand, calculation of hemodynamic parameters is complex and a multitude of data analysis packages are available. To some degree, this has prevented the establishment of meaningful numerical criteria with which to interpret DCE perfusion data.

ASL is perhaps the least well-studied perfusion technique and clinical availability remains limited. Signal-to-noise ratio is low particular for white matter regions. As the only technique that does not require contrast material, however, it can be employed in patients with poor renal function or limited intravenous access. Whereas repeated acquisition of DCE and DSC data is limited by total gadolinium dose, ASL measurements can be performed an unlimited number of times in rapid succession, so that the results of an intervention can be assessed immediately. The noninvasive nature of ASL perfusion is also advantageous when scanning in children. A positive linear correlation has been described between ASL and DSC perfusion, although the CBF results may be regionally similar but spatially different [48].

An emerging perfusion technique is steady-state susceptibility contrast CBV (SS-CBV) mapping. SS-CBV mapping acquires T2 or T2* maps without and with injection of a blood-pool contrast agent. One such agent is ferumoxytol, an ultra small superparamagnetic iron oxide nanoparticle that is confined to the intravascular space due to its larger size and longer half-life (~12 h) than gadolinium compounds. Christen et al. described a linear relationship between ferumoxytol dose (mg/kg) and ΔR2* (1/s) in the brains of seven volunteers, with SS-CBV images acquired to 1 mm³ isotropic spatial resolution [49]. Varallyay et al. examined 65 patients and found good correlations between SS-CBV and DSC perfusion techniques, with SS-CBV again providing superior spatial resolution [50]. Further studies into SS-CBV techniques and blood-pool contrast agents are necessary, as are direct comparisons to existing perfusion techniques as well as validation with histopathology in different pathologic conditions.

**Figure 3. Dynamic contrast-enhanced perfusion.** (A) Axial volume transfer coefficient and (B) plasma volume maps show no increased leakiness and mildly increased perfusion in the recurrent metastasis in the right frontal lobe. The color scale defines areas of increasing perfusion as changing from black to red to yellow. (C) Signal intensity–time curve used to model the arterial input function (red) reveals a rapid upslope with bolus injection of the contrast agent at 80 s with peak ΔR1 at approximately 95 s, followed by a rapid downslope due to the saline flush injection. Note the low background ΔR1 curve (green).

For color images please see online at www.futuremedicine.com/doi/pdf/10.2217/iim.13.50.

AF: Arterial function.
Clinical applications

■ Diagnosis & characterization of brain tumors

Conventional MRI is the technique of choice for the localization and differential diagnosis of cerebral mass lesions. In many cases, however, there is considerable overlap in the imaging features of different pathologic entities and narrowing the differential diagnosis is difficult. Perfusion imaging has been applied as a problem-solving tool in a wide array of clinical scenarios, for example, in distinguishing an abscess from a tumor or demyelinating plaque from normal white matter [51–53]. Perfusion imaging has proven to be exceptionally useful in the identification of primary CNS gliomas, of which approximately 22,500 new cases are diagnosed each year in the USA [54]. Accurate diagnosis, characterization and prognostication with noninvasive imaging is highly desirable. Perfusion techniques are well suited to imaging of primary brain tumors owing to their highly vascular nature [55]. Furthermore, the degree of vascularity has been correlated with glioma grade [56].

■ Distinguishing glioblastoma from metastasis

Metastasis is the most common brain tumor in adults and can have an imaging appearance similar to that of glioblastoma and other high-grade glioma. Clinical information is useful but not always definitive, as 30–50% of metastases are solitary [57], and primary brain tumors may occur in patients with systemic malignancies [58]. A study by Young and Setayesh used SE DSC perfusion to distinguish metastasis from high-grade glioma [59]. The study population included 40 patients with metastasis and 43 with high-grade glioma. The authors reported an rCBV ratio (rCBV of enhancing tumor compared with that of contralateral normal-appearing white matter) of 1.53 ± 0.79 in high-grade glioma versus 0.82 ± 0.40 in metastasis. At an rCBV threshold of 1.0, they achieved a diagnostic sensitivity of 88% and a specificity of 72%. The considerable overlap in intratumoral rCBV values between metastases and high-grade gliomas, however, limits any success in using perfusion MRI to distinguish between the two in routine practice.

DCE and ASL perfusion imaging of metastases have been less well studied. Ludemann et al. reported DCE perfusion data for 41 gliomas, six meningiomas and eight metastases using a novel three-compartment model, with the EES split into two subspaces using different exchange constants [60]. CBV was highest in meningiomas, intermediate in metastases and lowest in gliomas. One possible explanation for this conflicting result is the inclusion in the dataset of low-grade gliomas, tumors that tend not to be hypervascular. In our DCE experience, both high-grade gliomas and metastases tend to show increased plasma volume and capillary leakiness with little distinction in measurements. ASL studies are known to correlate well in general with other measures of perfusion; a recent qualitative study found a close correlation (r = 0.69) between CBF measurements obtained from gliomas and metastases [61]. Yamashita et al. examined PASL in five hemangioblastomas and 14 metastases and found higher absolute TBF and relative TBF values in hemangioblastomas, with the exception of a vascular renal cell carcinoma metastasis [62]. A relative TBF >3.3 had 100% sensitivity, 79% specificity and 84% accuracy for the diagnosis of hemangioblastoma.

Measuring disturbances in perfusion in the T2-hyperintense peritumoral abnormality immediately surrounding a brain tumor may be more useful than measuring the tumor itself. Perfusion imaging can take advantage of this infiltrative growth pattern unique to primary brain tumors. The peritumoral region of primary brain tumors may contain both edema and infiltrating tumor cells, while the peritumoral region of metastases usually contains only bland edema. Server et al. applied GRE DSC perfusion imaging to the peritumoral region in 40 patients with glioblastoma and 21 patients with metastasis [63]. The authors reported a rCBV of 1.8 ± 0.19 for metastases and 0.6 ± 0.1 for metastasis; a threshold value of 0.8 yielded a diagnostic sensitivity of 95% and a specificity of 92%. Cha et al. investigated the differences in two different metrics derived from DSC perfusion data, the peak height of the contrast curve and the percentage signal intensity recovered after bolus passage [64]. In the peritumoral region, average peak height was significantly higher for glioblastomas than for metastases. Percentage signal recovery was significantly reduced for metastases versus glioblastomas in both the peritumoral region (78 vs 83%) and in the enhancing portion of the tumor (63 vs 81%). An earlier study by Law et al. reported similar results, with mean peritumoral rCBV of 1.31 ± 0.97 for high-grade gliomas and 0.39 ± 0.19 for metastases [65].

■ Distinguishing high-grade glioma from lymphoma

Another common diagnostic dilemma in patients with one or more brain masses is to
distinguish high-grade glioma from primary CNS lymphoma. Both can present with heterogeneously enhancing mass lesion(s) and involvement of the corpus callosum. Accurate preoperative diagnosis (or at a minimum, consideration) of lymphoma is important as the treatments are different. Maximal tumor resection has been shown to improve survival in high-grade glioma but not in lymphoma. Therefore, in a case of suspected lymphoma, the patient usually requires only a biopsy and withdrawal of steroid medication if possible to avoid potentially false-negative histopathology results. Implications for radiation therapy, chemotherapy and prognosis also differ between the two tumors.

Studies of DSC perfusion imaging consistently demonstrate small increases in rCBV in lymphoma that are less than the large increases in rCBV that are observed in glioblastoma (Figure 4) [66]. The differences in perfusion reflect the underlying pathophysiology, as lymphomas demonstrate angiocentric growth that results in mild hyperperfusion, while high-grade gliomas have neovascularity with many new, immature and leaky blood vessels [67]. The mild increase in perfusion observed in lymphoma is often disproportionate to its aggressive appearance on conventional MRI (i.e., large, ill-defined, heterogeneous enhancing, cystic/necrotic changes).

A recent study employing a contrast leakage-correction technique found a corrected rCBV of 2.28 ± 0.60 for lymphoma and 5.47 ± 2.05 in glioblastoma [68]. Investigators are also beginning to study ASL perfusion in this setting. In a study of 26 patients, Yoo et al. found higher absolute CBF in high-grade glioma (92.1 ± 34.7 ml/100 g/min) than in lymphoma (53.6 ± 30.5 ml/100 g/min) [69]. Yamashita et al. reported similar findings, with significantly higher absolute CBF values in glioblastoma (91.6 ± 56.0 ml/100 g/min) compared with lymphoma (37.3 ± 10.5 ml/100 g/min) [70]. Weber et al. found lower increases in rCBF in CNS lymphoma than in glioblastoma using all three perfusion techniques [71]. We have observed similar trends using DCE perfusion, with lymphoma usually demonstrating a relatively mild increase in perfusion (Figure 5).

Predicting glioma grade
Perfusion imaging is useful in the grading of gliomas. Larger and more advanced tumors require greater vascularity [72], since a tumor that grows more than a few millimeters from an existing vessel must develop its own vascular supply. Tumor vessels, unlike normal host capillaries, are fragile, have a chaotic structure and lack a normal BBB [73]. Perfusion imaging can be used to estimate the increased microvascular density and capillary leakiness of these higher-grade neoplasms. Some caution is warranted in interpreting perfusion data, however, as hyperperfusion does not always signify high-grade pathology. For instance, low-grade gliomas with substantial oligodendroglial components may show greater than expected CBF [74]. Gangliogliomas may also show elevated perfusion [75] and juvenile pilocytic astrocytomas, despite their typically benign course, often also have malignant-appearing elevations in perfusion. Studies examining the potential

---

**Figure 4. Dynamic susceptibility contrast perfusion in lymphoma versus glioblastoma.** (A) Axial contrast T1-weighted image and (B) relative cerebral blood flow maps from (C) dynamic susceptibility contrast MRI in a patient with primary CNS lymphoma and (D) another patient with glioblastoma. The lymphoma shows mild, diffusely increased perfusion (relative cerebral blood flow: 1.8) in the bifrontal tumors, while the glioblastoma demonstrates heterogeneous, marked increased perfusion (relative cerebral blood flow: 5.6) in the occipital lobe and posterior callosal tumors. For color images please see online at www.futuremedicine.com/doi/pdf/10.2217/iim.13.50.
relationships between perfusion and tumor grade often exclude these tumor groups, focusing only on the astrocytic gliomas.

Studies of DSC perfusion have consistently described a good correlation between blood volume and glioma grade [76–80]. Higher-grade gliomas tend to have greater increases in perfusion than lower grade gliomas, although many studies have failed to show a significant difference between anaplastic gliomas and astrocytomas. Typically, a region of interest is drawn around the expected margins of the tumor based on contrast enhancement or another imaging feature. Young et al. have demonstrated histogram analysis as a viable alternative to region of interest placement, finding strong correlations between rCBV and glioma grade in both tumoral and peritumoral regions [81].

DCE perfusion offers estimations of \( K_{\text{trans}} \) and capillary leakiness that reflect underlying tumor neoangiogenesis. \( K_{\text{trans}} \) and plasma volume, which are both usually increased in high-grade gliomas, are considered independent metrics for patient prognosis. Nguyen et al. applied DCE perfusion to 46 patients with newly diagnosed gliomas using a phase-derived arterial input function and found that median plasma volume increased with glioma grade [82]. While early studies provided conflicting results [83,84], possibly owing to heterogeneity in choices of kinetic model, more recent data have suggested a strong correlation between \( K_{\text{trans}} \) and glioma grade [85,86]. A 2012 study by Zhang et al., using the extended two compartment Tofts model, found \( K_{\text{trans}} \) to be a statistically significant independent discriminator of low- and high-grade gliomas, with a sensitivity of 0.92 and a specificity of 0.85 [87]. Our preliminary results also suggest greater increases in \( K_{\text{trans}} \) and plasma volume in high-grade gliomas than in low-grade gliomas (Figure 6).

Studies of glioma grading using ASL perfusion have demonstrated an increased rCBF in gliomas of higher grade [87], and increased accuracy relative to conventional MRI in grading gliomas using ASL alone [88] and in combination with diffusion-weighted imaging (Figure 7) [89]. Wolf et al. reported increased absolute blood flow in high-grade gliomas (94.9 ± 71.7 ml/100 g/min) compared with low-grade gliomas (42.8 ± 22.0 ml/100 g/min) [90]. All but one low-grade glioma demonstrated a maximum CBF ≤50 ml/100 g/min.

**Predicting patient prognosis**

Perfusion in individual tumors has been correlated with prognosis by a number of investigators, most of whom relied on DSC perfusion data [91–98]. While early studies reported variable results, recent work has led to the consensus that a greater rCBV within a tumor confers a worse prognosis. Law et al. reported a median length of progression free survival (PFS) of 3585 days for patients with tumors of rCBV less than 1.75 compared with median PFS of 265 days for patients with tumors of rCBV greater than 1.75 [96]. When oligodendrogliomas and oligoastrocytomas, lower grade tumors that tend to be hyperperfused, were excluded, Bisdas et al. found significant correlations between rCBV and both PFS and WHO grade [97]. In that study, a maximum tumor rCBV of less than 3.8 predicted 1-year survival with 94% sensitivity and 73% specificity. A more recent study found significant correlations between rCBV and both overall survival and microvascular surface area at pathology [98]. The utility of DCE and ASL perfusion in predicting prognosis has not yet been well established.
Recent molecular work has identified subtypes of tumors with particular genetic characteristics that have prognostic implications. For example, the 1p/19q chromosomal codeletion is a strong predictor of favorable treatment response in patients with oligodendroglioma [99]. Early efforts to correlate perfusion with tumor genetics are underway. Law et al. reported preliminary DSC perfusion results in a retrospective study of 16 oligodendroglioma patients [100]. Increased rCBV values correlated with the presence of the 1p/19q chromosomal codeletion. Other investigators have reported similar results [101]. Similarly, MGMT promoter methylation status predicts a stronger response to temozolomide chemotherapy in patients with glioblastoma [102]. The utility of perfusion imaging in identifying MGMT promoter subtypes is less well established. Gupta et al. compared DSC perfusion characteristics of gliomas in 31 tumors with 46 without MGMT promoter methylation and, finding no significant difference in perfusion between the two groups [103]. Similar results were reported by Moon et al. [104].

**Selecting potential biopsy sites**
Perfusion imaging is useful to identify region(s) of higher-grade pathology within an individual heterogeneous tumor. As glioma grade is determined by the most aggressive portion of the tumor, tissue...
Sampling is ideally directed at the most malignant portion of the lesion. This becomes particularly important for tumors located in eloquent or deep brain areas that are not amenable to gross total resection. Contrast enhancement and conventional MRI are of limited value to guide tissue sampling [105–107]. A recent study by Weber et al. evaluated the utility of each of the three perfusion techniques in directing tissue sampling toward the most abnormal portions of the tumors that are likely to harbor areas of increased tumor cell proliferation and microvasculature [108]. In 61 glioma patients, they found that DCE and DSC perfusion had good (>50%), or perfect (100%), agreement in identifying tumor hot spots in all patients, respectively. When also including ASL perfusion, 18F-fluorothymidine PET and MRI spectroscopy imaging with DCE and DSC perfusion, they found good or perfect agreement in 80% of patients.

Evaluating treated brain tumors
Standard therapy for a newly diagnosed glioblastoma consists of maximal safe surgical resection, radiation therapy and concurrent and then adjuvant chemotherapy with temozolomide [109]. Lower grade tumors usually undergo some combination of resection, chemotherapy and radiation. For patients with disease that recurs on adjuvant temozolomide, several novel agents have recently become available, most of which act as inhibitors of neoangiogenesis [110–113]. The availability of these second-line agents and the potential for salvage treatments in the form of clinical trials have magnified the importance of imaging to accurately characterize treatment response and failure.

Tumor progression
Traditionally, recurrent or progressive disease was diagnosed when imaging revealed an increase in size of the enhancing portion of a tumor or the development of a new foci of enhancement [114]. More recently, response criteria typically used in clinical trials have been expanded to address the problem of similarities in the conventional imaging appearance of recurrent tumor and certain post-therapeutic changes [115,116]. Despite the recent updates, response criteria do not incorporate MRI perfusion information to determine true progression [117,118]. This is despite growing evidence that perfusion imaging can be useful to predict recurrent or progressive tumor by complementing conventional imaging and guiding treatment decisions. A recurrent tumor usually demonstrates increased perfusion and increased capillary leakiness, which may in some cases precede the development of an enhancing tumor. These changes may be observed using DSC perfusion with increased rCBV and decreased PSR, and using DCE perfusion with increased plasma volume and increased Ktrans (Figures 8 & 9). Further discussion and direct comparison to radiation injury follows in the next section.

Radiation injury
Radiation therapy has an important role in prolonging the length of survival for many patients with both primary and secondary brain tumors. Treatment may consist of whole-brain radiation therapy (secondary tumors only), partial-brain radiation therapy (primary or secondary tumors) or stereotactic radiosurgery (usually secondary tumors only). Therefore, the term radiation injury is applicable to both secondary
metastases from systemic cancers and primary brain tumors. Radiation injury can be classified as acute, early delayed or late delayed according to the time at which it manifests after completion of therapy [119–121]. Although many factors are involved, brain tolerance is related to the prescribed volume, total dose, fractionation and schedule of radiation therapy. Radiation injury has many synonyms including radiation necrosis, post-treatment effect and treatment-related change. Most of these are used interchangeably, although the term radiation ‘necrosis’ has traditionally been used to refer to late-delayed radiation injury with persistent enhancing mass lesions. By contrast, the term ‘pseudoprogression’ refers to a specific clinical form of early-delayed radiation injury in primary brain tumors only (usually glioblastomas). Despite differences in pathophysiology, MR perfusion imaging often shows a common theme with increased perfusion in viable tumor and decreased perfusion in injured or necrotic tissue.

Several investigators have used DSC perfusion imaging to distinguish residual or recurrent metastatic disease from radiation necrosis. Barajas et al. investigated the relative peak height (rPH) and PSR at DSC perfusion in 27 patients with recurrent enhancing lesions following γ knife radiosurgery [122]. Mean and maximum rPH values were significantly higher in the recurrent tumor group, while PSR was significantly lower in the recurrent tumor group. Mitsuya et al. studied DSC perfusion-derived rCBV values in 28 enhancing lesions that recurred after linear accelerator or γ knife radiosurgery [123]. Median ratio of rCBV to contralateral white matter was 3.5 for recurrent metastases and 1.0 for radiation effect (p < 0.0001) (Figure 10).

Studies separating recurrent tumor from radiation necrosis in cases of glioma have shown similar results. Barajas et al. reported rCBV, rPH and PSR at DSC perfusion in 57 glioma patients with recurrent enhancing lesions [124]. rPH and rCBV were significantly higher in recurrent glioblastoma than in radiation necrosis, whereas PSR was significantly lower. Larsen et al. applied DCE perfusion imaging to distinguish recurrent glioma from radiation necrosis in 19 patients, reporting that an absolute CBV threshold of 2.0 ml/100 g tissue detected tumor progression with 100% sensitivity and specificity [125]. Narang et al. reported success using a host of non-model-based DCE perfusion parameters to distinguish glioma from treatment effect [126]. Early studies of ASL perfusion suggest that it...
too is effective in distinguishing recurrent tumor from radiation necrosis [127].

At our institution, DCE perfusion imaging is routinely performed before initiation of therapy and at follow-up of both metastatic and primary CNS tumors. Ktrans is often greater in recurrent tumor than in radiation injury, but is elevated in both cases. Plasma volume is often greater in recurrent tumor and normal or decreased in radiation necrosis. Therefore, recurrent tumors usually present with an increased Ktrans and increased plasma volume (Figure 11). Unlike DSC perfusion, optimal threshold values have not been suggested in the literature; interpretation may also be complicated when patients present with recurrent tumor admixed with treatment effects (Figure 12).

Pseudoprogression in high-grade gliomas

Recent changes in standard of care therapy for glioblastoma have led to the description of a distinct class of tissue injury observed after chemoradiation. Termed as pseudoprogression, it consists of radiographic worsening in the early-delayed radiation time window (usually ≤3 months and up to 6 months following completion of radiation therapy) that spontaneously stabilizes or resolves over time [128,129]. Typically, the term pseudoprogression is reserved for cases of high-grade glioma treated with radiation and temozolomide, where the incidence is as high as 30% [130–133], although it has also been described with other chemotherapy agents. Interestingly, evidence suggests that development of pseudoprogression may be
a good prognostic sign, considering that it represents desirable therapy-induced death of tumor cells [134,135]. This probably reflects the higher incidence of pseudoprogression in patients with a methylated or inactivated MGMT promoter, a suicide DNA repair enzyme. In 50 patients, Brandes et al. reported that pseudoprogression occurred in 91% of methylated versus 41% of unmethylated patients (p = 0.002) [134].

Differentiating pseudoprogression from true progression is vital in making an informed treatment decision for a patient with a new or enlarging enhancing lesion. Effective therapy in pseudoprogression should be continued and the patient spared unnecessary repeat surgery and/or second-line chemotherapy that may be more toxic. There are also implications for clinical trials, as erroneously enrolling a patient with pseudoprogression, whose enhancing lesion would have spontaneously stabilized or resolved, would result in a false-positive result for the drug under study. de Wit et al. have suggested that patients with suspected pseudoprogression should be ineligible for Phase II clinical trials for this reason [128]. On the other hand, delayed treatment for a patient with true progression may result in unacceptable neurological decline and/or premature death.

Early studies of DSC perfusion have demonstrated that perfusion is greater in recurrent tumor than in pseudoprogression [116–118]. Young et al. found a lower rCBV, lower rPH and higher PSR in pseudoprogression compared with recurrent tumor (p = 0.009, p < 0.001 and p = 0.039, respectively) (Figure 13) [139]. Gahramanov et al. also found that a lower rCBV was a useful predictor of pseudoprogression, although they used the iron oxide nanoparticle blood-pool agent ferumoxytol rather than the standard gadolinium-based contrast agent [140]. Although not widely available, iron oxide nanoparticle agents may provide...
superior perfusion results due to their relative insensitivity to BBB disruptions, which obviate any corrections for potential contrast agent leakage. Iron oxide agents lack renal excretion and are, therefore, a viable alternative contrast agent in patients with renal failure or at risk for nephrogenic systemic fibrosis. DCE and ASL perfusion results specifically for pseudoprogression have not yet been reported.

Pseudoresponse in high-grade gliomas

Recently, several new drugs have been brought to market to target the neovascularization cascade involved in tumor growth. The two best studied agents are bevacizumab (Avastin®, Genentech, CA, USA), a monoclonal VEGF antibody, and cediranib (AZD2171), a VEGF inhibitor. Bevacizumab was recently approved by the FDA for the treatment of recurrent glioblastoma. Although the antiangiogenic effects of these agents are rapidly evident with diminution of enhancement at conventional MRI within hours, the overall survival benefit has been modest. Some patients will show expansion of the infiltrative, nonenhancing tumor, which often demonstrates intermediate-to-low T2 signal and mildly restricted diffusion. This decrease in enhancing tumor and increase in expansile nonenhancing tumor has been termed pseudoprogression. Only applicable in high-grade gliomas, this decrease in enhancing tumor would often result in classification as partial or complete response using the standard McDonald response criteria. The updated response assessment in neuro-oncology criteria allow increased nonenhancing disease as a criterion for progression, but offer relatively vague guidelines for quantifying such signal changes.

Despite the increased nonenhancing disease, the lack of enhancing disease to corroborate progression can be confusing. Experience with perfusion imaging in the setting of pseudoprogression is limited. Early studies suggest that a lower rCBV predicts longer PFS in patients treated with cediranib. At our institution, where patients receiving bevacizumab therapy are routinely followed with DSC and/or DCE perfusion imaging, we have observed that, typically, rCBV (DSC), Ktrans and plasma volume (DCE) are decreased, normal or minimally increased in patients with pseudoprogression (Figures 14 & 15). These results contrast with usual progression patterns where both perfusion and capillary leakiness metrics are markedly increased, limiting the clinical utility of perfusion imaging in these patients. Felhaber et al. reported a single patient with recurrent glioblastoma receiving bevacizumab where DSC and ASL perfusion showed increasing perfusion metrics prior to increased enhancing tumor, suggesting that there is a useful role for perfusion imaging in a subset of patients receiving antiangiogenic therapy. Imaging of pseudoprogression will probably continue to be an area of active research as imaging techniques are refined and new chemotherapeutics are developed.

Conclusion

Perfusion MRI is a convenient, noninvasive means of obtaining functional information about the hemodynamic state of a tissue of interest. This is of particular use in brain tumor imaging where more aggressive lesions typically display
greater vascularity. Of the three main MR perfusion techniques, DSC perfusion is the most widely available and best studied. DCE perfusion offers greater spatial resolution and additional information about capillary leakiness, but data analysis is more complicated and the literature is less mature. ASL perfusion is most forgiving technically, as it does not require gadolinium administration; however, it suffers from poor availability, low spatial resolution and low signal-to-noise ratio.

While MRI perfusion techniques have been shown to be of value in tumor imaging and have proven to be useful in daily practice, guidelines for data acquisition, postprocessing and interpretation have not been standardized. This has slowed the more widespread adoption into clinical practice and delayed the incorporation of perfusion metrics into standardized response criteria. Further study in the optimal acquisition parameters is necessary to enable multiinstitutional pooling of data. These parameters should be feasible in any busy clinical setting and not simply reflect ideal parameters used in research settings. In addition, further advances in the mathematical modeling of intravenous contrast and exchanges between intravascular and extravascular extracellular spaces in normal and leaky pathological states could help improve the accuracy of imaging-based measurements.

**Future perspective**

In the next 5–10 years, MRI perfusion techniques will probably become more widely available and better studied, increasing their stature as vital clinical and research tools that enable reliable predictions about clinical outcome. Further advancements in perfusion software will lead to automated or semiautomated analyses of MRI perfusion data, removing many of the operator and site-specific variabilities that hinder contemporary comparisons. Further advancements will be facilitated by newer perfusion techniques, such as steady-state imaging, and newer intravenous contrast and molecular agents. These will be enabled by the widespread adoption of hybrid PET/MR imaging systems, just as 3T scanners have become as common as 1.5 T scanners today. These PET/MR systems will enable multiparametric functional, anatomical and molecular imaging with unparalleled tissue contrast and concordance between different imaging techniques. As an established review of peritumoral abnormality may help discriminate between glioblastoma and metastasis.

**Executive summary**

**Dynamic susceptibility contrast T2*-weighted MRI perfusion**
- T2* technique is rapid and has robust signal changes.
- T2* technique may be limited by susceptibility artifacts from hemorrhage and bone/air interfaces.
- The analysis methods are relatively simple.
- Preload correction and/or post hoc correction (e.g., arterial input function and gamma variate curve fitting) is usually advocated to compensate for leakage.
- This is the best studied of the main perfusion techniques.

**Dynamic contrast-enhanced T1-weighted MRI perfusion**
- T1 technique measures leakiness or permeability as well as perfusion.
- T1 perfusion offers improved spatial resolution when compared to T2* perfusion.
- T1 perfusion is relatively resistant to susceptibility artifacts and hemorrhage.
- More complex analysis methods and postprocessing is required.

**Arterial spin labeling**
- No intravenous contrast is necessary.
- ASL may require longer imaging times and result in lower signal to noise than the other techniques.
- ASL is not as well studied in pathology as the other main perfusion techniques.

**Clinical applications**
- Evaluation of peritumoral abnormality may help discriminate between glioblastoma and metastasis.
- Perfusion in lymphoma is usually less than in high-grade glioma.
- In gliomas:
  - Higher-grade gliomas usually show higher perfusion than lower grade gliomas.
  - Volume transfer coefficient and perfusion should be considered as independent markers.
  - Increased perfusion is correlated with decreased patient survival.
- Perfusion may correlate with genetic and molecular markers.

**Tumor progression**
- Radiation injury including pseudoprogression usually show lower perfusion than progressive tumor.
- Overlap in perfusion metrics between radiation injury and tumor progression groups remains problematic in clinical care.
- The role of perfusion imaging with antiangiogenic therapy remains uncertain due to direct effects upon the vasculature by treatment that may no longer reflect tumor aggressiveness.
technology with decades of data available, MRI perfusion will become a standard tool against which newer imaging techniques are evaluated.

**Financial & competing interests disclosure**

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

**References**

Papers of special note have been highlighted as:

- of interest


- Addresses some of the controversies involved in leakage correction for dynamic susceptibility contrast perfusion.


- Excellent discussion of dynamic susceptibility contrast modeling techniques.


Role of MRI perfusion in improving the treatment of brain tumors


Classic paper describing popular modeling techniques that are still used today.


difficult from metastatic brain tumors based on quantitative blood flow measurement. *Neuroradiology* 54(8), 809–813 (2012).


88. Discusses using arterial spin labeling in glioma grading.


* Examines the utility of dynamic contrast-enhanced perfusion in distinguishing between recurrent tumor and radiation injury in treated tumors.

121 Ozsunar Y, Mullins ME, Kwon K et al. Glioma recurrence versus radiation necrosis: A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced...
139 Fussell & Young. Imaging Med. (2013) 5(5) future science group
144 Sorensen AG, Batchelor TT, Zhang WT et al. A ‘vascular normalization index’ as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69(13), 5296–5300 (2009).